 Connection
Glenn Furuta to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Glenn Furuta has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.424 |
|
|
|
-
Furuta GT, Atkins D, Capocelli KE, de Zoeten EF, Fleischer D, Menard-Katcher C. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013 Oct; 57(4):e25.
Score: 0.295
-
Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb; 129(2):456-63, 463.e1-3.
Score: 0.065
-
Nguyen N, Burger C, Skirka S, White S, Smith M, Menard-Katcher C, Furuta GT, Mehta P. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 10 01; 77(4):536-539.
Score: 0.036
-
Olbrich CL, Simerly L, de Zoeten EF, Furuta GT, Spencer LA. Climbing New Mountains: How Antibodies Blocking a4?7 Integrins Tamed Eosinophilic Inflammation of the Intestinal Tract. Dig Dis Sci. 2019 08; 64(8):2068-2071.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|